Medchemexpress LLC Acetamide, 2-[[7-(3,4-dimethoxyphenyl)-2-quinoxalinyl)amino]-N-methyl- | 1513879-21-4 | 99.9% | 352.39 | 25 MG

Supplier:  Medchemexpress LLC 25MGHY18748

BQR-695 is a PI4KIIIβ inhibitor with IC50s of 80 nM for human PI4KIIIβ and 3.5 nM for the *Plasmodium* variant of PI4KIIIβ. For research use only.

• Treatment with 0.5 μM of either KAI407 or BQR695 causes GFP-PHOsh2 to redistribute to the parasite plasma membrane, consistent with depletion of intracellular PI4P upon inhibition of PfPI4K function.
• BQR695 shows no evidence of toxicity against mature red blood cells (RBCs).
• It induces a schizont-stage arrest indistinguishable from that observed in imidazopyrazine-treated parasites and exhibits cross-resistance with the imidazopyrazine-resistant lines.
• DMSO: 50 mg/mL (141.89 mM; requires ultrasonic; hygroscopic DMSO has a significant impact on solubility, use newly opened DMSO).
• Powder: -20°C for 3 years, 4°C for 2 years.
• In solvent: -80°C for 2 years, -20°C for 1 year.

Catalog No. 50-003-85930